Clinical trial
A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)
NCT01669226 is registered in ClinicalTrials.gov with Shanghai Gynecologic Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)
- Lead sponsor
- Shanghai Gynecologic Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- July 31, 2016
- Enrollment
- 215 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
bulky stage iiic and iv epithelial ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma